SCHEMBL71677

SCHEMBL71677

CCOC(=O)CNC(=O)c1ccc(Nc2ccccc2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.48
PPID Q08752 1/20 0.46
EGLN1 Q9GZT9 1/20 0.44
ALDH1A1 P00352 6/20 0.44
LMNA P02545 3/20 0.44
HSD17B10 Q99714 3/20 0.43
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 2/20 0.42
KDM4E B2RXH2 2/20 0.42
NPY1R P25929 1/20 0.42
NPY2R P49146 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69555 0.83 EGLN1 (0.56) EGLN1ALDH1A1MAPTMEN1KMT2A
SCHEMBL70720 0.82 EGLN1 (0.62) HPGDPPIDEGLN1ALDH1A1LMNA
SCHEMBL70737 0.82 RAB9A (0.60) HPGDPPIDALDH1A1LMNAHSD17B10
SCHEMBL28543158 0.82 SMN1; SMN2 (0.53) HPGDALDH1A1LMNAHSD17B10MAPT
SCHEMBL27851432 0.78 MEN1 (0.49) HPGDALDH1A1HSD17B10MAPTMAPK1
SCHEMBL70192 0.77 MAPT (0.57) HPGDPPIDALDH1A1LMNAMAPT
SCHEMBL27039815 0.77 SMN1; SMN2 (0.57) HPGDEGLN1ALDH1A1LMNAHSD17B10
SCHEMBL29601352 0.77 SMN1; SMN2 (0.57) HPGDEGLN1ALDH1A1LMNAHSD17B10
SCHEMBL1221369 0.72 RAB9A (0.66) HPGDPPIDALDH1A1LMNAMAPT
SCHEMBL29031128 0.72 SMN1; SMN2 (0.47) HPGDALDH1A1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 HPGD 482/4885PPID 562/4885EGLN1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.